Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ProBioGen Upholds Strong Patent Position in Viral Vaccine Manufacturing Field

Published: Thursday, October 31, 2013
Last Updated: Thursday, October 31, 2013
Bookmark and Share
Company offers licenses and contract research services to human and animal vaccine companies.

ProBioGen has announced that the Opposition Division of the European Patent Office has confirmed ProBioGen’s patent, covering the production of Modified Vaccinia Ankara (MVA) virus on permanent duck cell lines for viral vaccines, in all claims.

ProBioGen was first to demonstrate that MVA can be produced efficiently on duck cell lines like its proprietary AGE1.CR.pIX® cell line.

Modified Vaccinia Ankara (MVA) virus is a vector with proven safety profile for therapeutic and prophylactic vaccination against infectious diseases and tumors.

“The decision of the Patent Office confirms ProBioGen’s strong position in the vector-based vaccine field. The upheld IP protection of this pioneering platform technology also provides planning security for our existing and for future licensees”, states Dr. Wieland Wolf, CEO of ProBioGen.

ProBioGen developed the AGE1.CR.pIX® duck cell line along with robust industrial vaccine production processes for a wide spectrum of viruses, including MVA. AGE1.CR.pIX® grows in true suspension in chemically defined media.

In contrast to the traditionally used cells from embryonated chicken eggs, AGE1.CR.pIX®, derived from a muscovy duck, is devoid of adverse retroviral activity.

Hence, the complex and costly production processes with chicken eggs are replaced by a safe, fully scalable, and cost-effective production platform, which is easily transferrable.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ProBioGen, Eucodis Sign Agreement
Company has signed an exclusive license agreement with Eucodis Bioscience to commercialize C-LiNK, a novel antibody drug conjugation technology.
Wednesday, April 20, 2016
ProBioGen in Biosimilar Deal with Bio Farma Indonesia
Trastuzumab development and transfer for first indonesian on-site production.
Thursday, October 29, 2015
ProBioGen and Tizona Therapeutics Sign Agreement
ADCC-enhancement for innovative cancer therapy, produced via ProBioGen’s accelerated CMC development path.
Tuesday, October 06, 2015
Anti-Ebola MVA Vaccine Produced on Avian AGE1.CR® Cell Line in Clinical Trials
"Production of the first ever batch of MVA for a clinical trial using a cell line".
Wednesday, June 03, 2015
20 Years ProBioGen
Invests €20 million in mammalian manufacturing expansion.
Wednesday, September 10, 2014
ProBioGen Signs GlymaxX ADCC Enhancement Technology License Deal
A non-exclusive commercial multi-product licensing agreement with Novartis.
Tuesday, June 24, 2014
ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology
GlymaxX® manufacturing technology improves bispecific antibody activity for solid tumor treatment.
Wednesday, March 05, 2014
ProBioGen and Emergent BioSolutions Partner
ProBioGen announces expansion of commercial licenses with Emergent BioSolutions for AGE1.CR® viral vaccine manufacturing production platform.
Tuesday, December 17, 2013
ProBioGen Signs Deal with TOP 10 Pharma Company for Therapeutic Antibody Platform
Another global pharma company has licensed ProBioGen’s GlymaxX® ADCC-enhancement technology.
Wednesday, February 20, 2013
Ceva and ProBioGen Signs Multi-product License Agreement
Ceva takes commercial license for ProBioGen’s AGE1.CR® cell line for viral vaccine production.
Friday, March 16, 2012
ProBioGen and Inhibrx Sign License Deal on GlymaxX® ADCC Technology
GlymaxX® ADCC technology and mammalian cell line development and manufacturing services used to advance therapeutic antibodies.
Friday, October 28, 2011
ProBioGen Signs Therapeutic Protein Process Development Contract with Virdante Pharmaceuticals
ProBioGen to contribute producer cell line development and process engineering for Virdante’s therapeutic protein.
Wednesday, April 28, 2010
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Apricot Kernels Pose Risk of Cyanide Poisoning
Eating more than three small raw apricot kernels, or less than half of one large kernel, in a serving can exceed safe levels. Toddlers consuming even one small apricot kernel risk being over the safe level.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
A lncRNA Regulates Repair of DNA Breaks in Breast Cancer Cells
Findings give "new insight" into biology of tough-to-treat breast cancer.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!